Skip to main content

Agreement with Accelera

Glucox Biotech has signed an agreement with Accelera Srl, Milano, Italy. Accelera will evaluate pharmacokinetics and time course of brain uptake of Glucox’ lead compounds in mice.

Two of Glucox’ NOX4 small molecule inhibitors have been shown to protect brain from nerve cell damage in a situation of induced acute ischemic stroke. To further elucidate the positive action of these compounds, time course of brain uptake will be investigated and evaluated.

Leave a Reply

Your email address will not be published.

Let's Shape the Future Together

Connect with Glucox Biotech to explore collaborative opportunities and discover our innovative research.